Literature DB >> 31071310

Implications of the dynamic nature of metabolic health status and obesity on risk of incident cardiovascular events and mortality: a nationwide population-based cohort study.

Yun Kyung Cho1, Yu Mi Kang2, Jee Hee Yoo3, Jiwoo Lee3, Joong-Yeol Park3, Woo Je Lee3, Ye-Jee Kim4, Chang Hee Jung5.   

Abstract

AIMS: We hypothesized that transitions in metabolic health status and obesity affect the cardiovascular (CV) risk and mortality in population with metabolically healthy obesity (MHO).
METHODS: This study enrolled 514,866 participants from the Korean National Health Insurance Service-National Sample Cohort. Changes in metabolic health status and obesity from the baseline examination in 2009-2010 to the next biannual health examination in 2011-2012 were determined. Study participants were categorized into four groups: (1) metabolically healthy, non-obese (MHNO), defined as BMI < 25 kg/m2 and no or one metabolic risk factor; (2) metabolically unhealthy, non-obese (MUNO), defined as BMI < 25 kg/m2 and ≥2 metabolic risk factors; (3) MHO, defined as BMI ≥ 25 kg/m2 and no or one metabolic risk factor; and (4) metabolically unhealthy, obese (MUO), defined as BMI ≥ 25 kg/m2 and ≥2 metabolic risk factors. The study subjects were followed-up from 2011 to 2015 for cardiovascular events, CV mortality and all-cause mortality.
RESULTS: Among the subjects classified as MHO in 2009-2010, 45.6% were classified as MHO in 2011-2012, whereas 11.6%, 6.0%, and 36.8% were classified as MHNO, MUNO, and MUO, respectively. The risk of CV events was higher in baseline MHO group than MHNO group (HR, 1.14; 95% CI, 1.05-1.24). However, in baseline MHO group, CV mortality was not increased (HR, 0.85; 95% CI, 0.69-1.06) and all-cause mortality was even lower than that of MHNO group (HR, 0.86; 95% CI, 0.79-0.93). Compared to the stable MHO subjects, the risk of CV events was significantly higher in the subjects who transitioned from MHO to MUO with multivariate-adjusted HRs of 1.24 (95% CI: 1.00-1.54). When weight loss and progression to metabolic unhealthy phenotype occur simultaneously in the MHO population, the all-cause mortality was increased compared to the stable MHO group (HR, 1.96; 95% CI, 1.45-2.65).
CONCLUSIONS: Subjects with MHO constitute a heterogeneous group. Our finding supports that evolving to a metabolically unhealthy status and losing weight simultaneously is associated with the adverse outcome in the MHO population.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiovascular disease risk; Cardiovascular mortality; Metabolic syndrome; Mortality; Obesity

Mesh:

Year:  2019        PMID: 31071310     DOI: 10.1016/j.metabol.2019.05.002

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  15 in total

1.  Transition of Metabolic Phenotypes and Risk of Atrial Fibrillation According to BMI: Kailuan Study.

Authors:  Maoxiang Zhao; Wenjuan Du; Qianqian Zhao; Yating Chen; Bin Li; Zhonghui Xie; Zihao Fu; Nan Zhang; Xiaowei Cheng; Xiaoqian Li; Siyu Yao; Miao Wang; Chi Wang; Shouling Wu; Hao Xue; Yang Li
Journal:  Front Cardiovasc Med       Date:  2022-06-28

2.  Triglyceride-Glucose Index Predicts Cardiovascular Outcome in Metabolically Unhealthy Obese Population: A Nationwide Population-Based Cohort Study.

Authors:  Yun Kyung Cho; Hwi Seung Kim; Joong-Yeol Park; Woo Je Lee; Ye-Jee Kim; Chang Hee Jung
Journal:  J Obes Metab Syndr       Date:  2022-06-13

3.  Metabolic phenotypes and risk of colorectal cancer: a systematic review and meta-analysis of cohort studies.

Authors:  Golnoosh Goodarzi; Hadis Mozaffari; Tahereh Raeisi; Fatemeh Mehravar; Bahman Razi; Maryam Lafzi Ghazi; Nazila Garousi; Shahab Alizadeh; Parisa Janmohammadi
Journal:  BMC Cancer       Date:  2022-01-21       Impact factor: 4.430

4.  Age-Related Associations of Low-Density Lipoprotein Cholesterol and Atherosclerotic Cardiovascular Disease: A Nationwide Population-Based Cohort Study.

Authors:  Han Na Jung; Min-Ju Kim; Hwi Seung Kim; Woo Je Lee; Se Hee Min; Ye-Jee Kim; Chang Hee Jung
Journal:  J Am Heart Assoc       Date:  2022-05-02       Impact factor: 6.106

5.  Differential Effect of Metabolic Health and Obesity on Incident Heart Failure: A Nationwide Population-Based Cohort Study.

Authors:  Hwi Seung Kim; Jiwoo Lee; Yun Kyung Cho; Joong-Yeol Park; Woo Je Lee; Ye-Jee Kim; Chang Hee Jung
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-25       Impact factor: 5.555

6.  The role of APOE in cognitive trajectories and motor decline in Parkinson's disease.

Authors:  Sungyang Jo; Seon-Ok Kim; Kye Won Park; Seung Hyun Lee; Yun Su Hwang; Sun Ju Chung
Journal:  Sci Rep       Date:  2021-04-09       Impact factor: 4.379

7.  Wrist circumference as a novel predictor of transition from metabolically healthy to unhealthy phenotype in overweight/obese adults: a gender-stratified 15.5-year follow-up.

Authors:  Pouria Mousapour; Maryam Barzin; Majid Valizadeh; Maryam Mahdavi; Farzad Hadaegh; Fereidoun Azizi; Farhad Hosseinpanah
Journal:  BMC Public Health       Date:  2021-12-13       Impact factor: 3.295

8.  Hospitalization for heart failure incidence according to the transition in metabolic health and obesity status: a nationwide population-based study.

Authors:  You-Bin Lee; Da Hye Kim; Seon Mee Kim; Nan Hee Kim; Kyung Mook Choi; Sei Hyun Baik; Yong Gyu Park; Kyungdo Han; Hye Jin Yoo
Journal:  Cardiovasc Diabetol       Date:  2020-06-13       Impact factor: 9.951

9.  Metabolic health is a determining factor for incident colorectal cancer in the obese population: A nationwide population-based cohort study.

Authors:  Yun Kyung Cho; Jiwoo Lee; Hwi Seung Kim; Joong-Yeol Park; Woo Je Lee; Ye-Jee Kim; Chang Hee Jung
Journal:  Cancer Med       Date:  2020-11-20       Impact factor: 4.452

10.  Dynamic changes in metabolic health status in Chinese adults: Multiple population-based surveys in Shanghai, China.

Authors:  Yihui Yang; Yanyun Li; Jianfeng Pei; Minna Cheng; Wanghong Xu; Yan Shi
Journal:  J Diabetes Investig       Date:  2021-06-05       Impact factor: 4.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.